Modality
Small Molecule
MOA
FcRni
Target
CDK4/6
Pathway
Epigenetic
Crohn's
Development Pipeline
Preclinical
~Jun 2024
→ ~Sep 2025
Phase 1
Dec 2025
→ Nov 2030
Phase 1Current
NCT03931886
2,153 pts·Crohn's
2025-12→2030-11·Recruiting
2,153 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-074.6y awayPh2 Data· Crohn's
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Recruit…
Catalysts
Ph2 Data
2030-11-07 · 4.6y away
Crohn's
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03931886 | Phase 1/2 | Crohn's | Recruiting | 2153 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| Fixabrutinib | Verve | Phase 1 | RET |